Literature DB >> 29772402

Serious adverse events following Normal Pressure Hydrocephalus surgery.

Vikas Kotagal1, Elizabeth Walkowiak2, Jason A Heth2.   

Abstract

OBJECTIVE: Recent Normal Pressure Hydrocephalus (NPH) practice guidelines describe a serious adverse event (SAE) rate following surgery of 11%. PATIENTS &
METHODS: We conducted a retrospective review of 162 consecutive patients who have undergone work-up at our center's multidisciplinary NPH clinic over a 47 month time period (2/2014-12/2017). Of these, 22 ultimately underwent neurosurgical ventricular shunt surgery as treatment for NPH. Clinical records were reviewed for SAEs categorized as possibly/probably/definitely related to NPH surgery.
RESULTS: In 10/22 (45.5%) operated subjects, there were 11 qualifying SAEs over this 3-year period: 1 central nervous system infections, 4 subdural hematomas, 2 seizures resulting in hospitalization, 1 catheter malfunction, 2 perioperative AEs, and 1 death of uncertain cause. Eight SAEs were coded as probably/definitely related. Six occurred >3 months from the time of surgery.
CONCLUSIONS: SAEs following NPH surgery are common. Additional studies are needed to determine the long-term safety of NPH surgery in older adults.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Frail elderly; Gait; Long term adverse events; Neurosurgery; Normal Pressure Hydrocephalus; Ventriculoperitoneal shunt

Mesh:

Year:  2018        PMID: 29772402     DOI: 10.1016/j.clineuro.2018.05.008

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  1 in total

Review 1.  Can the Treatment of Normal-Pressure Hydrocephalus Induce Normal-Tension Glaucoma? A Narrative Review of a Current Knowledge.

Authors:  Yasin Hamarat; Laimonas Bartusis; Mantas Deimantavicius; Paulius Lucinskas; Lina Siaudvytyte; Rolandas Zakelis; Alon Harris; Sunu Mathew; Brent Siesky; Ingrida Janulevicienė; Arminas Ragauskas
Journal:  Medicina (Kaunas)       Date:  2021-03-03       Impact factor: 2.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.